MetLife Inc., the insurer reducing variable annuity sales by more than half, said rivals that are expanding are probably retaining less funds to back the retirement products.
“The companies that hold the lowest amount of capital against their VA business are by and large the same companies who are most aggressively selling VAs today,” Bill Wheeler, MetLife's president of the Americas region, said at a conference on Tuesday. The sales expansion is “literally a doubling-down in this industry,” he said.
MetLife, the largest U.S. life insurer, has been scaling back from variable annuities to cut risks tied to market fluctuations. The contracts can guarantee that clients' assets will increase in value even when equities fall. Prudential Plc's Jackson National, the No. 12 seller of variable annuities in 2007, is now the biggest, followed by Lincoln National Corp.
Hot Beverage Stocks To Own Right Now: Allergan Inc. (AGN)
Allergan, Inc., a multi-specialty healthcare company, discovers, develops, and commercializes specialty pharmaceutical, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets worldwide. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment offers a range of pharmaceutical products, including ophthalmic products for chronic dry eye, glaucoma therapy, ocular inflammation, infection, allergy, and retinal diseases; Botox for the therapeutic and aesthetic indications; skin care products for acne, psoriasis, and other skin care products; eyelash growth products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery; obesity intervention products, including the La p-Band System and the Orbera Intragastric Balloon System; and facial aesthetics products. The company also offers Contigen for the treatment of urinary incontinence due to intrinsic sphincter deficiency. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, and ambulatory surgery centers, as well as to medical practitioners, including ophthalmologists, neurologists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, bariatric surgeons, pediatricians, urologists, and general practitioners. Allergan, Inc. has strategic research collaboration agreements with ExonHit Therapeutics S.A.; Spectrum Pharmaceuticals, Inc.; and Pieris AG. The company was founded in 1948 and is headquartered in Irvine, California.
Advisors' Opinion:- [By Garrett Cook]
Salix Pharmaceuticals (NASDAQ: SLXP) shares shot up 4.52 percent to $167.05 on report of takeover talks with Allergan. Allergan (NYSE: AGN) is set to acquire Salix Pharmaceuticals in a deal probably worth more than $10 billion, according to Dow Jones Newswires.
- [By John Udovich]
Large cap serial acquirer�Valeant Pharmaceuticals International Inc (NYSE: VRX) is teaming up with activist investor�Bill Ackman to pursue large cap Botox maker Allergan, Inc (NYSE: AGN), but stocks like Cutera, Inc (NASDAQ: CUTR), Cynosure, Inc (NASDAQ: CYNO), PhotoMedex Inc (NASDAQ: PHMD) and Syneron Medical Ltd (NASDAQ: ELOS)�actually offer investors more exposure to the growing anti aging and aesthetics market (Note: See my recent article: These Small Caps Seek to Treat Your Crow�� Feet and Double Chin (RVNC & KYTH)). To begin with, Valeant Pharmaceuticals International has a wide focus on neurology, dermatology and infectious diseases�but acquiring the maker of Botox won�� be its first foray into the aesthetic market�because earlier this year, the company completed its acquisition of Solta Medical Inc (NASDAQ: SLTM) -�a designer, developer, manufacturer and marketer of�energy-based medical device systems for aesthetic applications.�And while�Allergan, Inc may be most well known for Botox, its actually a pretty big�company focused on a diverse range of areas, including ophthalmic pharmaceuticals, dermatology, neuroscience, urology and cosmetics���meaning the following stocks offer investors better exposure to the aesthetics market:
- [By Ben Levisohn]
UBS analyst Marc Goodman explains why he raised Allergan (AGN) to Buy from Neutral following yesterday’s financial results and cost-cutting moves:
Reuters Allergan Chief Executive David PyottInvestors have been waiting for 2 Allergan events: a restructuring and an accretive deal. Given the Friday PR for the conf call [yesterday], many investors were expecting a deal to be announced today and thus were disappointed from that perspective. But the cost cutting was solid and viewed positively (on top of the very strong qtr), and mgt couldn’t have been more confident that it can get a deal done in time. Now we wait for this deal. Can Allergan create close to as much ST value as Valeant (VRX) can with its cost cuts?
Before�[yesterday] Valeant’s cost synergy targets (R&D) were already suspect because Valeant mgt indicated that it would cut $900M of a $1.1B budget and yet still pursue attractive late-stage pipeline projects. Allergan pointed to >$200M of post-approval commitments and >$300M of spend to accomplish those projects. Hence, we had already assumed that Valeant would need to change either its synergies or sacrifice projects (we assume cut projects). This is not only what it did with both Medicis and B&L but eliminating R&D is part of the b-model. With [yesterday's] cuts Allergan�� cost base is ~$3.5B and Valeant�� planned $2.7B of synergies would account for >75% of costs. Cost synergies are critical to determine deal accretion for Valeant, and so it will be interesting to see what Valeant will do with its aggressive targets.
Shares of Allergan are little changed at $171.22 at 2:10 p.m. today, while Valeant has dropped 1.3% to $123.97.
- [By Ben Levisohn]
“Shelter From the Storm,” helped make Bob Dylan’s Blood on the Tracks one of the best albums. Getting shelter from generic competition for Restatis has helped boost Allergan’s (AGN) shares today.
Best Net Payout Yield Stocks To Invest In 2014: Encana Corporation(ECA)
Encana Corporation and its subsidiaries engage in the exploration for, development, production, and marketing of natural gas, oil, and natural gas liquids. The company owns interests in resource plays that primarily include the Greater Sierra, Cutbank Ridge, Bighorn, and Coalbed Methane resource plays located in British Columbia and Alberta, as well as the Deep Panuke natural gas project offshore Nova Scotia in Canada. It also holds interests in resource plays comprising the Jonah in southwest Wyoming, Piceance in northwest Colorado, Haynesville in Louisiana, and Texas resource play, including east Texas and north Texas. The company serves primarily local distribution companies, industrials, energy marketing companies, and other producers. Encana Corporation was founded in 1971 and is headquartered in Calgary, Canada.
Advisors' Opinion:- [By Monica Wolfe]
Encana (ECA)
Manning & Napier�� fifth largest holding is in Ecana. The guru holds on to 27,376,066 shares of Unilever, representing 2.4% of their total holdings and 3.71% of the company�� shares outstanding. Over the past quarter, Manning & Napier increased their position 0.22% by purchasing 60,930 shares. They purchased these shares in the first quarter price range of $17.25 to $21.42, with an estimated average quarterly price of $18.90. Since then the price per share has increased approximately 21.8%.
- [By Arjun Sreekumar]
But now, with gas prices above $4 per Mcf, some producers are either resuming or ramping up operations in gassier plays. For instance, Encana (NYSE: ECA ) announced in February that it intends to increase its gas rig count in the Haynesville shale by three this year, citing the play's recently improved profitability.
- [By Aaron Levitt]
Recently, Canada�� largest natural gas producer EnCana (ECA) highlighted one of the most ignored ways to profit from the energy sector; ECA announced that they will place around 5.2 million acres worth of oil and gas reserves/wells in Alberta, Canada into a new subsidy called PrairieSky Royalty. EnCana will sell shares of the firm in order to raise some much needed cash. PrairieSky should IPO by mid-June.
Best Net Payout Yield Stocks To Invest In 2014: SPDR S&P International Consumer Discretionary Sector ETF (IPD)
SPDR S&P International Consumer Discretionary Sector ETF (the Fund) seeks to provide investment results that correspond generally to the total return performance of the S&P Developed Ex-U.S. BMI Consumer Discretionary Sector Index (the Index), an index that tracks the consumer discretionary sector of developed global markets outside the United States. The Index represents the non-United States consumer discretionary sub-industry of developed countries included in the S&P Broad Market Index (the Global BMI Index). The Global BMI Index captures the full universe of institutionally investable stocks in developed and emerging markets with float-adjusted market capitalizations of at lease $100 million. The Fund�� investment advisor is SSgA Funds Management, Inc. Advisors' Opinion:- [By WilliamBriat]
The SPDR S&P International Consumer Discretionary Sector (NYSE: IPD) is an ETF that tracks the consumer discretionary sector of developed global markets. Holdings include luxury brand stock juggernaut LVMH Moët Hennessy – Louis Vuitton SA and Swedish luxury brand stock multinational retail clothing company H & M Hennes & Mauritz AB.
Best Net Payout Yield Stocks To Invest In 2014: ACCO Brands Corp (ACCO)
ACCO Brands Corporation, incorporated on October 26, 1970, is one of the suppliers of branded school and office products. The Company sells its products through many channels that include the office products resale industry as well as through mass retail distribution and e-tailers. It designs, develops, manufactures and markets a variety of traditional and computer-related office products, school supplies and paper-based time management products. Through a focus on research, marketing and innovation, it seeks to develop new products that meet the needs of its consumers and commercial end-users, and support its brands. ACCO Brands is organized into three business segments: ACCO Brands North America, ACCO Brands International and Computer Products Group. It sells its products primarily to markets located in the United States, Northern Europe, Canada, Brazil, Australia and Mexico. On May 1, 2012, it completed the merger (Merger) of the Mead Consumer and Office Products Business (Mead C&OP) with a wholly-owned subsidiary of the Company.
Its office, school and calendar product lines use name brands such as AT-A-GLANCE, Day-Timer, Five Star, GBC, Hilroy, Marbig, Mead, NOBO, Quartet, Rexel, Swingline, Tilibra, Wilson Jones and many others. Its products and brands are not confined to one channel or product category and are designed based on preference. It manufactures approximately half of its products, and specify and source approximately the other half of its products, mainly from Asia. Its office products, such as stapling, binding and laminating equipment and related consumable supplies, shredders and whiteboards, are used by businesses. These business end-users purchase their products from its customers, which include commercial contract stationers, retail superstores, mass merchandisers, wholesalers, resellers, mail order and Internet catalogs, club stores and dealers. It also supplies some of its products directly to commercial and industrial end-users. Its school products include n! otebooks, folders, decorative calendars, and stationery products. It distributes its school products primarily through traditional and online retail mass market, grocery, drug and office superstore channels. It also supplies private label products within the school products sector. Its calendar products are sold throughout all channels where it sells office or school products, and it also sell direct to consumers.
ACCO Brands North America and ACCO Brands International
ACCO Brands North America and ACCO Brands International manufacture, source and sell traditional office products, school supplies, calendar products and document finishing solutions. ACCO Brands North America comprises the U.S. and Canada, and ACCO Brands International comprises the rest of the world, principally Europe, Latin America, Australia, and Asia-Pacific.
Its office, school and calendar product lines use name brands such as AT-A-GLANCE, Day-Timer, Five Star, GBC, Hilroy, Marbig, Mead, NOBO, Quartet, Rexel, Swingline, Tilibra, Wilson Jones and many others. Its office products, such as stapling, binding and laminating equipment and related consumable supplies, shredders and whiteboards, are used by businesses. These business end-users purchase their products from its customers, which include commercial contract stationers, mass merchandisers, retail superstores, wholesalers, resellers, mail order and Internet catalogs, club stores and dealers. It also supplies some of its products directly to commercial and industrial end-users.
Its school products include notebooks, folders, decorative calendars, and stationery products. It distributes its school products primarily through traditional and online retail mass market, grocery, drug and office superstore channels. It also supplies private label products within the school products sector. Its calendar products are sold throughout all channels where it sells office or school products, and it also sells direct to consumers.
! Computer Products Group
The Computer Products Group designs, distributes, markets and sells accessories for laptop and desktop computers and tablets and smartphones. These accessories primarily include security products, iPad covers and keypads, smartphone accessories, power adapters, input devices such as mice, laptop computer carrying cases, hubs, docking stations and ergonomic devices. The Computer Products Group sells mostly under the Kensington, Microsaver and ClickSafe brand names, with the majority of its revenue coming from the U.S. and Western Europe.
All of its computer products are manufactured to its specifications by third-party suppliers, principally in Asia, and are stored and distributed from its regional facilities. Its computer products are sold primarily to consumer electronics retailers, information technology value-added resellers, original equipment manufacturers and office products retailers.
The Company competes with, 3M, Avery Dennison, Blue Sky, Carolina Pad, Dominion BlueLine, Esselte, Fellowes, Franklin Covey, Hamelin, House of Doolittle, Newell Rubbermaid, Smead, Spiral Binding, Belkin, Fellowes, Logitech and Targus.
Advisors' Opinion:- [By John Kell]
Acco Brands Corp.(ACCO) expects its 2013 results to come in ahead of analysts’ estimates as the office-products supplier projected fourth-quarter revenue that beat expectations. Shares of the company, whose brands include Day-Timer, At-a Glance and Mead, rose 5.1% to $6.59 in light premarket trading.
- [By Will Ashworth]
While some might consider private equity firms to be at the high-end of the cycle, I see Fortress just now coming into its own. Fortress recently announced it took a paper loss on Bitcoin. Not to worry, FIG’s 2013 distributable earnings per share increased by almost 70% to $0.88, its highest level since its IPO. I see it moving higher than $10 in 2014.
Cheap Stocks to Buy: ACCO Brands (ACCO)I don�� know about you but I definitely use several of its products on a regular basis. In fact, right here on my desk beside my computer is a small, Five Star notebook for jotting down ideas. I grew up on Hilroy notebooks, a brand brought to the table in its 2012 merger with MeadWestvaco�� (MWV) Consumer and Office Products division. MWV shareholders received one-third of an ACCO share for every MWV share. Since the deal was completed, ACCO stock has lost 42% of its value.
- [By Travis Hoium]
What: Shares of office supply maker ACCO Brands (NYSE: ACCO ) fell as much as 13% in early trading today before settling in at a 5% drop.
- [By Lisa Levin]
Office Supplies: The industry dropped 1.51% by 10:50 am. The worst performer in this industry was ACCO Brands (NYSE: ACCO), which declined 1.3%. ACCO Brands shares have gained 2.30% over the past 52 weeks, while the S&P 500 index has surged 21.67% in the same period.
Best Net Payout Yield Stocks To Invest In 2014: BIOLASE Inc (BIOL)
BIOLASE, Inc., formerly BIOLASE Technology, Inc., incorporated in 1987, is a medical technology company that develops, manufactures and markets lasers, and markets and distributes dental imaging equipment and other related products designed for applications and procedures in dentistry and medicine. The Company's dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other specialists to perform a range of dental procedures, including cosmetic and complex surgical applications in a minimally invasive manner. The Company also manufactures and sells disposable products and accessories for its laser systems. The Company's Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed. The Company also markets flexible fibers and hands pieces. For the Company's ezlase system, the Company sells tooth whitening gel kits. In April 2012, it purchased 159 Waterlase MD Turbo laser systems from Henry Schein, Inc.
The Company's Waterlase Dentistry consists of two product lines Waterlase systems and Diode systems. In July 2011, the Company introduced the Biolase DaVinci Imaging line of imaging products, which enabled the Company to offer digital diagnostic solutions to complement the minimally invasive dental treatment solutions offered by its Waterlase and Diode dental systems. The Company added the distribution of the NewTom cone beam computed tomography (CBCT), to its imaging product line. The integration of the Company's laser products with imaging offers dental professionals the Total Technology Solution, which provides imaging capabilities for early diagnosis and minimally invasive treatment with its Waterlase iPlus and iLase laser technologies.
The Company's all-tissueWaterlase dental laser systems consist of the Waterlase iPlus, the Waterlase MD Turbo, and the Waterlase MDX 300 and 450, both introduced in February 2012. Each of these systems is designed around the Company's yttrium scandi! um gallium garnet (YSGG) laser technology that refers to the laser crystal used in the Waterlase system, which contains the elements erbium, chromium and yttrium, scandium, gallium and garnet. This crystal laser produces energy with specific absorption and tissue interaction characteristics optimized for dental applications. HydroPhotonics refers to the interaction of YSGG lasers with water to produce energy to cut tissue. It is minimally invasive and can cut hard tissue, such as bone and teeth, and soft tissue, such as gums or skin, without the heat, vibration, or pressure associated with traditional dental treatments. By eliminating heat, vibration, and pressure, the Company's Waterlase systems eliminate the need for anesthesia.
The Waterlase systems incorporate an ergonomic handpiece and a control panel located on the front of the system with precise preset functionality to control the mix of laser energy, air, and water, as well as the pulse rate. The Waterlase iPlus incorporates the iLase wireless diode laser that can be utilized for unexpected soft-tissue cases in an adjacent treatment room, controlling bleeding, and temporary pain relief.
The Company's Diode laser systems in dentistry consist of the ezlase and iLase, semiconductor diode lasers to perform soft tissue, hygiene, cosmetic procedures, teeth whitening, and temporary pain relief. The Company's ezlase system serves the markets of general, cosmetic, orthodontic and hygienic procedures. It features a pulse mode, ComfortPulse, which allows the tissue to cool between pulses and reduces the need for anesthesia for many common procedures. Other features include a wireless foot pedal control, disposable single-use tips, color touch screen activation with up to fifteen procedure based pre-sets, a whitening hand piece, a rechargeable battery pack, and a wall mount.
The Company's imaging systems include the Company's design and distribution of extra-oral and intra-oral dental digital imaging devices. The Co! mpany's e! xpansion into digital imaging systems enables the Company to offer diagnostic solutions to complement the minimally invasive dental treatment solutions offered by the Company's Waterlase and Diode dental systems. The Company provides both high-precision intuitive diagnosis and treatment planning solutions. The Company's Biolase DaVinci Imaging systems include the D3D, a three dimensional (3D) CBCT, and portable digital x-ray and intra-oral camera devices.
The NewTom VGi is a small-footprint CBCT system that offers medical grade imaging technology. In addition to producing up to image resolution with medical grade rotating anode technology, SafeBeam technology automatically adjusts radiation dosage. The Company's Medical systems include the Diolase 10 Diode Laser. As of December 31, 2011, the Company has sold approximately 8,700 Waterlase systems, including over 4,700 Waterlase MD and iPlus systems, and more than 19,000 laser systems in total in over 60 countries. As of decembe31, 2011, the Company�� other products under development address ophthalmology, dermatology, orthopedics, podiatry, and other medical and consumer markets.
The Company competes with Lares Dental Research, Fotona d.d., KaVo Dental GmbH, Lambda SpA, J Morita Manufacturing Corp., Syneron Medical Ltd, Deka Laser Technologies, Inc. Ivoclar Vivadent, Inc., Dentsply, Inc., Royal Philips Electronics and Sirona Dental Systems, Inc.
Advisors' Opinion:- [By Roberto Pedone]
Another under-$10 stock that's starting to trend within range of triggering a big breakout trade is Biolase (BIOL), which develops, manufactures and markets laser systems for dental and medical applications. This stock has been trending modestly higher in 2013, with shares up by 15.9%.
If you take a look at the chart for Biolase, you'll notice that this stock has been uptrending strong for the last month and change, with shares pushing higher from its low of $1.47 to its recent high of $2.25 a share. During that uptrend, shares of BIOL have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BIOL within range of triggering a big breakout trade.
Traders should now look for long-biased trades in BIOL if it manages to break out above some near-term overhead resistance levels at $2.25 to $2.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 311,533 shares. If that breakout hits soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $3.07 a share to $3.50 or $3.70 a share.
Traders can look to buy BIOL off weakness to anticipate that breakout and simply use a stop that sits right below its 50-day moving average of $1.85 a share. One can also buy BIOL off strength once it clears those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
- [By James E. Brumley]
Looking for a quick, high-odds bullish trade? Then look for further than BIOLASE Inc. (NASDAQ:BIOL). This small medical equipment company has had nothing less than a miserable 2013, falling from a peak above $6.00 in April to a multi-year low of $1.16 on Wednesday. But, the size and scope of that plunge from BIOL has also dropped all the tell-tale hints that a rebound is nigh.
- [By Roberto Pedone]
One health care player that's starting to trend within range of triggering a major breakout trade is Biolase (BIOL), which is a medical technology company that develops, manufactures and markets laser systems for dental and medical applications. This stock is off to a decent start in 2013, with shares up 12%.
If you take a look at the chart for Biolase, you'll notice that this stock has been trending sideways and consolidating for the last two months, with shares moving between $1.64 on the downside and $2.24 on the upside. Shares of BIOL have now started to spike higher right off its 200-day moving average of $1.87 a share. That spike is quickly pushing shares of BIOL within range of triggering a major breakout trade above the upper-end of its recent sideways trading chart pattern.
Traders should now look for long-biased trades in BIOL if it manages to break out above some near-term overhead resistance levels at $2.15 to $2.24 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 627,655 shares. If that breakout triggers soon, then BIOL will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.
Traders can look to buy BIOL off any weakness to anticipate that breakout and simply use a stop that sits right below some key near-term support levels at $1.85 to $1.80 a share. One can also buy BIOL off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Best Net Payout Yield Stocks To Invest In 2014: Cogent Communications Group Inc.(CCOI)
Cogent Communications Group, Inc. provides high-speed Internet access, Internet Protocol, and communications services primarily to small and medium-sized businesses, communications service providers, and other bandwidth-intensive organizations in North America, Europe, and Japan. It offers on-net services to bandwidth-intensive users, such as universities, other Internet service providers, telephone companies, cable television companies, and commercial content providers; and multi-tenant office buildings, including law firms, financial services firms, advertising and marketing firms, and other professional services businesses. The company also provides its on-net services in carrier-neutral colocation facilities, Cogent controlled data centers, and single-tenant office buildings. In addition, it offers off-net services to businesses that are connected to its network primarily by means of last mile access service lines obtained from other carriers primarily in the form of p oint-to-point TDM, POS, SDH, and/or carrier ethernet circuits. Further, the company provides voice services; and Internet connectivity to customers that are not located in buildings directly connected to the company?s network. Additionally, it operates 43 data centers that allow customers to co-locate their equipment and access its network. Cogent Communications Group, Inc. was founded in 1999 and is headquartered in Washington, D.C.
Advisors' Opinion:- [By Ali Berri]
In trading on Friday, telecommunications services shares were relative laggards, down on the day by about 0.01 percent. Meanwhile, top decliners in the sector included NQ Mobile (NYSE: NQ), down 4.1 percent, and Cogent Communications Holdings (NASDAQ: CCOI), off 2.4 percent.
- [By WWW.DAILYFINANCE.COM]
SAN FRANCISCO -- Netflix's videos are streaming through Comcast's Internet service at their highest speeds in 17 months, thanks to a recent deal that bought Netflix a more direct connection to Comcast's (CMCSA) network. The data released Monday by Netflix (NFLX) may become another flash point in a debate about whether the Federal Communications Commission should draw up new rules to ensure that all online content providers are treated the same by Internet service providers. The equal-treatment doctrine, known as Net neutrality, has become a thornier topic since January when a federal appeals court overturned the FCC's regulations on the issue. Net neutrality is also drawing more attention as Comcast tries to gain approval of its proposed $45 billion purchase of Time Warner Cable (TWC), another large Internet service provider. As the world's largest Internet video subscription service, Netflix has long supported Net neutrality as a way to prevent online service providers from giving better treatment to websites willing to pay additional fees for the privilege. Nevertheless, Netflix agreed in mid-February to pay an undisclosed sum to Comcast Corp. to create a new avenue for its videos to reach Comcast's service. Netflix previously had been paying third-party vendors such as Cogent Communications Group (CCOI) and Akamai Technologies (AKAM) to deliver its content to Comcast. Some analysts suspect Netflix may be saving money by paying Comcast directly instead of the vendors, but the specifics remain unknown as part of a confidentiality agreement. The arrangement clearly seems to paying off for Netflix subscribers who are among the nearly 21 million households and businesses that rely on Comcast's high-speed Internet service to watch movies and television shows. Comcast delivered Netflix video at an average rate of 2.5 megabits per second during March. That was a 66 percent increase from a recent low of 1.51 megabits per second in January. The March perform
- [By James O'Toole]
Netflix (NFLX) relies heavily on third parties -- primarily Cogent Communications (CCOI) -- to deliver content from its servers to Internet service providers. Traditionally, broadband companies and bandwidth providers like Cogent haven't charged one another, on the assumption that traffic that flows back and forth over their networks will even out over time.
- [By Lee Jackson]
Cogent Communications Group Inc. (NASDAQ: CCOI) provides high-speed Internet access, Internet protocol (IP) and communications services, primarily to small and medium-sized businesses, communications service providers and other bandwidth-intensive organizations in North America, Europe and Japan. The consensus price target for the stock is $35. Investors receive a 1.7% dividend. Cogent closed Thursday at $32.12.
Best Net Payout Yield Stocks To Invest In 2014: Interleukin Genetics Inc (ILIU.PK)
Interleukin Genetics, Inc., incorporated on March 28, 2000, is a personalized health company, which develops genetic tests to provide information to manage health and specific health risks. The Company�� business focuses on personalized health, by providing genetic tests with clinical value. Its tests are made available through marketing partners or directly to end users. The Company's primary business focus and strategy is to continue the Company's commercialization efforts with its PST genetic test. In addition, the Company plans to continue to develop and sells tests for its own business needs under the Inherent Health brand.
The Company's genetic tests that are being commercialized includes PST is a genetic test, which analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease; Weight Management Genetic Test determines whether a low fat, low carbohydrate or balanced diet may normal or vigorous exercise, which is needed to lose existing body fat; Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis; Heart Health Genetic Test is designed to identify genetic predisposition to excess inflammation, which is a risk factor for heart attack, and Wellness Select Genetic Test allows buyers to purchase any combination of Inherent Health genetic tests at a discounted price. The Company is also focusing its genetic test development efforts on the development of an Osteoarthritis, or OA, genetic test to identify individuals at increased risk for severe OA.
Genetic Test for Risk of Periodontal Disease
PST is a genetic test that analyzes genetic variations associated with inflammation and identifies individuals who are at increased risk for more severe periodontal disease. The PST genetic test identifies specific polymorphisms (genetic variations) in genes that! regulate the production of interleukin cytokines.Interleukin-1 (IL-1) is well-established as one of the critical regulators of periodontal disease, and studies in non-human primates have shown that drugs specifically blocking IL-1 alone or IL-1 plus TNFa reduces tissue destruction even when the bacterial challenge is not reduced.
Inherent Health Brand of Genetic Tests
The Company's Weight Management Genetic Test helps take the guesswork out of finding an effective diet and exercise solution by revealing actionable steps to achieve weight goals based on genetics. The test provides new information beyond traditional assessments, so that nutritional intake and fitness routines can be tailored for improved, sustainable results. This test identifies five SNPs in four human genes: fatty acid binding protein 2 (FABP2); adrenergic receptor beta 2 (ADRB2 two variations); adrenergic receptor beta 3 (ADRB3); and peroxisome proliferator-activated receptor gamma (PPAR- ). These markers are involved in certain physiological pathways relating to body weight. Certain patterns of markers are associated with differential response to certain diet and exercise regimens.
The Company has conducted a number of studies that demonstrate a gene-diet interaction based on the multi-locus patterns . In the original study, 311 overweight/obese (body mass index, 27-40 kg/m2), nondiabetic, premenopausal, generally healthy women were randomly assigned for 12 months to either the Atkins-like ( low carbohydrate), Zone-like (low carbohydrate), LEARN-like (balanced), or Ornish-like (low fat) diets for the primary purpose of losing weight. The data collected in that study included dietary intake assessment (three unannounced 24-hour recalls for each time point administered by a dietitian and analyzed using NDS-R, University of Minnesota), anthropometric measures including weight, and related physiological variables, all collected at baseline, two, six, and 12 months.
Bone Health Genetic T! est
The Company's Bone Health Genetic Test is designed to identify whether an individual is more likely to be susceptible to spine fractures and low bone mineral density associated with osteoporosis. Although it typically starts later in life, early intervention can help prevent osteoporosis. Preventive measures can reduce the risk for bone loss and fractures, which in the case of vertebral fractures leads to a hunched over appearance. The test identifies a SNP in each of three genes involved in processes that affect bone; estrogen receptor alpha (ER1 Xba1), vitamin D receptor (VDR), and interleukin-1 (IL-1). Certain patterns of variations are associated with increased risk of spine fracture and/or low bone mineral density. The test can be used as an aid to making diet, exercise, and other lifestyle choices to maintain and improve bone health.
Nutritional Needs Genetics Test
The Company's Nutritional Needs Genetics Test is designed to identify DNA variations in genes crucial to B-vitamin metabolism and the ability to manage oxidative stress. Individuals with certain variations in these genes may be at increased risk for ineffective utilization of B-vitamins and potential for cell damage caused by oxidative stress, both of which can in some cases lead to increased risk for certain diseases. The test identifies the presence or absence of human genotypic markers methylenetetrahydrofolate reductase (MTHFR) and transcobalamin II (TCN2) involved in vitamin B metabolism and markers superoxide dismutase 2 (SOD2), glutathione S-transferase 1 deletions (GSTM1), paraoxonase 1 (PON1), X-ray repair cross complementing group 1 (XRCC1) in response to oxidative stress. Certain variations are associated with less efficient B-vitamin metabolism or reduced activity of endogenous anti-oxidant systems. The test may be used to aid individuals in deciding whether to supplement their diet with B vitamins and/or antioxidants.
Genetic Test Pipeline
The Company is focusing! its gene! tic test development efforts on programs, including Osteoarthritis Genetic Test. OA is the common adult joint disease, increasing in frequency and severity in all aging populations. The estimated U.S. prevalence is 20-40 million patients or five times that of rheumatoid arthritis. The Company's OA program plans to investigate whether interleukin gene variations together with several other inflammatory gene variations is associated with the occurrence of multi-joint OA for the development of a genetic risk assessment test.
Advisors' Opinion:- [By Brian Marckx]
Interleukin Genetics, Inc. (ILIU.PK) develops genetic tests focused on personal health. Through applied genetics research and scientific collaborations, the company has made significant progress in understanding how genetic make-up can affect an individual's predisposition and risk of suffering from certain diseases. Interleukin's research has specifically focused on a form of genetic variation called single nucleotide polymorphisms (SNP) and how it can have an impact on a person's health. The company has applied this knowledge in the development of genetic tests focused on areas such as weight management, cardiovascular health and periodontal disease. Interleukin sells its Inherent Health line of tests, which launched in 2009, to the consumer market and maintains a CLIA-certified lab at its headquarters in Waltham, Massachusetts, where consumers send test samples for processing.
No comments:
Post a Comment